Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proteomics01:33

Proteomics

8.5K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Are lazertinib and osimertinib comparable for treating advanced <i>EGFR</i>-mutant non-small cell lung cancer?-insights and limitations from the MARIPOSA study.

Journal of thoracic disease·2026
Same author

Survival and relapse of Danish patients with thymic epithelial tumors.

Acta oncologica (Stockholm, Sweden)·2026
Same author

Low-grade myofibroblastic sarcoma of the orbit in a 68-year-old woman: a case report.

Orbit (Amsterdam, Netherlands)·2026
Same author

Correlation of TP53 Mutations With p53 Expression and Ki-67 Index in Pulmonary Large Cell Neuroendocrine Carcinomas.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2026
Same author

Durable Response to Sequential ROS1-TKIs in Metastatic Squamous NSCLC With EZR-ROS1 Fusion: A Case Report.

Clinical lung cancer·2026
Same author

Improvement of Diagnostics in NSCLC Patients with <i>MET</i> Exon 14 Mutations Using Complementary DNA/RNA-NGS and Identification of Two Novel Exonic Splicing Mutations.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Oct 15, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.3K

Functional Proteomic Profiling of Triple-Negative Breast Cancer.

Irina Gromova1, Jaime A Espinoza2, Morten Grauslund3

  • 1Genome Integrity Unit, Danish Cancer Society Research Center, Cancer Proteomics Group, DK-2100 Copenhagen, Denmark.

Cells
|October 23, 2021
PubMed
Summary
This summary is machine-generated.

Triple-negative breast cancer (TNBC) exhibits diverse signaling pathways, with PI3K/AKT/mTOR activation being most common. Proteomic profiling reveals potential targeted therapies for specific TNBC subtypes.

Keywords:
breast cancerproteomicsreverse phase protein arraysignaling pathway profilingtriple negative breast cancer

More Related Videos

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

16.5K
Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
10:37

Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification

Published on: November 15, 2017

12.2K

Related Experiment Videos

Last Updated: Oct 15, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.3K
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

16.5K
Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
10:37

Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification

Published on: November 15, 2017

12.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Triple-negative breast cancer (TNBC) lacks estrogen receptor, progesterone receptor, and HER2 expression.
  • Conventional chemotherapy is the primary treatment for TNBC due to its receptor-negative status.

Purpose of the Study:

  • To quantitatively profile signaling intermediates in TNBC.
  • To identify TNBC subtypes amenable to targeted therapies.

Main Methods:

  • Utilized reverse phase protein array (RPPA) and immunohistochemistry.
  • Analyzed proteomic data using supervised and unsupervised methods on 44 TNBC samples.
  • Profiled activation states of 84 signaling intermediates and phosphoproteins.

Main Results:

  • Identified heterogeneous activation across multiple signaling pathways in TNBC.
  • PI3K/AKT/mTOR signaling was the most frequently observed activated pathway.
  • Found potential therapeutic targets including oncogenic KIT, cytokeratin 15, and Erk1/2 expression.

Conclusions:

  • TNBC is characterized by diverse signaling pathway activation.
  • Specific molecular profiles may guide individualized therapeutic strategies for TNBC patients.
  • Further research into targeted therapies based on identified signaling pathways is warranted.